Catalyze Expands to Switzerland

Catalyze Expands to Switzerland

Amsterdam, February 22, 2018– Closely succeeding the successful expansion to Copenhagen, Denmark, Catalyze has now also expanded its operations to Switzerland. This presents the next step of the company’s international growth plan. Switzerland is home to many pharmaceutical and diagnostic companies and represents a strong eco-system in Zurich, Lausanne and Basel, consisting of many start-ups, accelerator programs, high-quality research institutes and large groups such as Novartis and Roche.

Catalyze provides clients and partners with the necessary help in obtaining funding for their R&D projects, and supports them with business matchmaking services to build strong European consortia.

Theodoor Rutgers and Jalal Es-Sbai, Co-founders of Catalyze, comment on the expansion. Theodoor explains:

“After Switzerland recently regained full membership to the EU’s Horizon2020 program, we have experienced a strong growth in demand for our services. As they only recently re-joined, we notice that local knowledge of what funding is available and how to apply for these funds is still limited. Therefore, support from our Strategic Funding Unit (SFU) and highly specialized funding consultants comes at the right time.” 

Jalal continues:

“Because these funds were previously inaccessible, many local companies may not have built the European wide partnerships necessary to apply for them. Catalyze is happy to support Swiss companies and academia to build strong European consortia to be able to successfully compete for funding. The network of Catalyze of over 1200 partners offers a unique pool to generate new opportunities and collaborative projects. This expansion will allow Catalyze to better provide its services to existing and new clients situated not only in Switzerland but also in neighboring areas as Italy and France.”

Furthermore, Virginia Ballotta, the newly appointed country manager and business developer, is devoted to the success of Catalyze in Switzerland. As a brief introduction we asked her the following questions:

• What are the expectations for Catalyze in Switzerland?

We expect that opening an office in Switzerland will help us establish new strategic partnerships and gain a deeper insight into the local funding landscape. Through our presence in the territory, we will be able to interact with our local customers on a regular basis, to better understand their needs and develop new, bespoke funding strategies.

• What is your vision for Catalyze in Switzerland?

Switzerland has been ranked as the most innovative country in the world by the Global Innovation Index (GII) 2017 for the seventh time in a row1. Our mission at Catalyze is to help innovators carry their ideas forward and Switzerland offers ample opportunities to accomplish this. I believe that the synergistic collaboration between Catalyze and Swiss researchers and companies will boost the development of biomedical innovations for the benefit of the whole society.

• What are your first steps as a country manager going to be?

I will start by consolidating existing partnerships and laying the foundations for new ones. I will make sure that Swiss researchers and start-up companies know that we are easily reached and here to help!

The expansion to Switzerland grants the opportunity for further success and influence in the industry while providing clients with the highest quality services and knowledge. This is supported by a solid network built and preserved over years. Catalyze maintains successful and long-lasting relationships due to its client focus and its unique full-service offering.
Virginia Ballotta can be reached at + 41 76 583 11 84 or email: virginia.ballotta@catalyze.nl for further information.

About Catalyze

Catalyze is a market leader in obtaining funding for biomedical and healthcare innovations, as well as for projects in the related ICT, eHealth, and big data fields. Catalyze helps leading researchers and companies secure financing for ambitious R&D projects, from early-stage scientific research up to clinical stage development. Catalyze combines subsidies, loans and venture capital, tailored to the client’s plans and ambitions. Catalyze supports a variety of Life Sciences developments including, but not limited to, diagnostics, pharmaceuticals, medical devices and healthcare solutions. The company has a strong passion for the latest technological innovations and its top consultants work with the best clients and projects in Europe and beyond. Catalyze has the ambition to further expand internationally from its headquarters in The Netherlands and offices in selected countries.

# # #
If you would like more information about this topic, please contact Catalyze at +31 (0)20 723 44 00 or email at info@catalyze.nl

Sources
1“Indicator Rankings & Analysis.” Global Innovation Index, 2017,
www.globalinnovationindex.org/analysis-indicator.

All services

In our approach we combine both non-dilutive and dilutive funding. Let’s start working on your project together now!

 

Welcome at Catalyze!

Catalyze uses cookies in order to improve your user experience. By using this website you agree to our policy.

Go back or